Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BTAI BioXcel Therapeutics
29.750-1.200-3.88%
Trading Session
01/31 12:44 ET
High
30.810
Open
30.480
Turnover
6.77M
Low
29.140
Pre Close
30.950
Volume
225.50K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Karuna Appoints Former BioXcel Exec as Chief Commercial Officer
BioXcel Executive Joins Karuna Therapeutics as Chief Commercial Officer
06:51 AM EST, 01/31/2023 (MT Newswires) -- Karuna Therapeutics (KRTX) said Tuesday that it has named Will Kane chief commercial officer, effective Feb. 6. Kane has previously served as executive vice
Brokerages Set BioXcel Therapeutics, Inc. (NASDAQ:BTAI) PT at $51.78
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) has been given an average rating of "Moderate Buy" by the nine analysts that are currently covering the company, MarketBeat reports. One analyst
Insider Selling: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Insider Sells $1,500,000.00 in Stock
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) insider Frank Yocca sold 50,000 shares of BioXcel Therapeutics stock in a transaction on Friday, January 20th. The stock was sold at an average p
Goldman Sachs Adjusts Price Target on BioXcel Therapeutics to $26 From $16, Maintains Neutral Rating
10:12 AM EST, 01/26/2023 (MT Newswires) -- BioXcel Therapeutics (BTAI) has an average buy rating and a price target range of $20 to $82, according to analysts polled by Capital IQ. Price: 31.94, Chang
BioXcel Therapeutics Price Target Raised to $26.00/Share From $16.00 by Goldman Sachs
BioXcel Therapeutics Is Maintained at Neutral by Goldman Sachs
BioXcel Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/26/2023 -16.48% Goldman Sachs $16 → $26 Maintains Neutral 01/03/2023 134.5% HC Wainwright & Co. $85 → $
Goldman Sachs Maintains Neutral on BioXcel Therapeutics, Raises Price Target to $26
Goldman Sachs analyst Corinne Jenkins maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Neutral and raises the price target from $16 to $26.
BioXcel Therapeutics (NASDAQ:BTAI) Shares Down 8.6% Following Insider Selling
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating)'s share price traded down 8.6% during trading on Wednesday after an insider sold shares in the company. The company traded as low as $29.82 and l
Company Overview
More
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. The firm offers IGALMI, a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. It also develops BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of prostate cancer and solid tumors that are refractory to checkpoint inhibitors. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
CEO： Dr. Vimal Mehta, PhD
Market： NASDAQ
Listing Date： 03/08/2018
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet